Bristol Myers Squibb reports positive ACTION-1 results: stock pre-market at EUR 51.72
Published on 10/13/2026 at 08:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS- Bristol Myers Squibb reported positive interim ACTION-1 results on October 12, 2026.
- The Phase 3 trial of RYZ101 met its primary progression-free survival endpoint.
- The stock was at EUR 51.72 at Lang & Schwarz at 8:08 a.m. CEST on October 13, 2026.
Bristol Myers Squibb announced positive topline results from the interim analysis of its Phase 3 ACTION-1 trial on October 12, 2026, according to a Bristol Myers Squibb release. The stock was at EUR 51.72 at Lang & Schwarz on October 13, 2026, at 8:08 a.m. CEST.
Pre-market indication
Lang & Schwarz showed a bid of EUR 51.52 and an ask of EUR 51.92. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.
ACTION-1 reaches primary endpoint
The ACTION-1 study evaluated RYZ101, RayzeBio’s investigational radiopharmaceutical therapy, against investigator’s choice of standard care in patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors who had progressed after Lu177-based therapy. Bristol Myers Squibb said the trial met its primary endpoint with a statistically significant and clinically meaningful improvement in progression-free survival, while safety results were consistent with the known RYZ101 profile. The company said participants will continue to be followed for overall survival and that detailed results are expected at a future medical meeting. The release also said the FDA granted RYZ101 Orphan Drug Designation in August 2026 and that RayzeBio plans to engage with the FDA on next steps toward a regulatory submission.
What matters today
The next dated company event is Bristol Myers Squibb’s Q3 2026 results conference call scheduled for October 29, 2026. ACTION-1 is a Phase 3 trial identified as NCT05477576. RYZ101 is based on Actinium-225, identified in the release as 225Ac-DOTATATE.
Market context: Market report S&P 500.
